17 October 2022 | News
New technology improves cell purity, isolation efficiency, and increases recovery of target cells for scalable cell therapy manufacturing
image credit- businesswire
Thermo Fisher Scientific Inc. has unveiled the Gibco CTS DynaCellect Magnetic Separation System (DynaCellect) to help cell therapy developers easily move from process and clinical development to commercial manufacturing.
This next-generation cell isolation, cell activation, cell depletion and Dynabeads magnetic beads removal instrument provides a scalable, flexible, automated and closed system to help optimize the cell therapy manufacturing process.
As a result, DynaCellect helps ensure the right cells are isolated and failures in manufacturing are minimized. With the cell therapy market poised for rapid growth, this evolution in cell therapy manufacturing can support the commercialization of high performing therapies as well as the development of the next class of cell therapy breakthroughs.
Designed to be used with Dynabeads, the DynaCellect system delivers exceptional performance, high-throughput capacity and process flexibility while enabling an end-to-end closed process. Cell therapy manufacturers utilizing the DynaCellect system can leverage a highly efficient workflow that reliably delivers high-performing target cells.
With processing speed and scalability, this technology helps manufacturers quickly optimize their protocol design and move into commercial production. For patients, this means more options for effective new therapies they can trust.